DT-7012 (anti-CCR8 monoclonal antibody)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for DT-7012 (anti-CCR8 monoclonal antibody), covering 2025-10-09 to 2025-10-09. Get the full timeline:
Most recent: Clinical Trial Update: A Phase 1, Multicenter, Open-label, Prospective, First-in-human Dose-escalation Clinical Trial of Domain Therapeutics' Anti-CCR8 Monoclonal Antibody (DT-7012) in Patients With Relapsed or Refractory Cutaneous T-cell Lymphomas (CTCL) [EARLY_Phase 1]